



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	93.89
Trade Time:	4:00 PM ET Feb 21, 2018
Change:	0.04 (0.043%)
Day Range	93.80 - 95.72
52-Week Range	88.32 - 147.17
Volume	4,179,650

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Feb 21, 2018*
[Celgene Receives Antitrust Clearance for Juno Acquisition](#)
- Feb 17, 2018*
[OTEZLA[®] \(Apremilast\) Phase III Data Showed Significant Improvements in Patients with Active Behçet's Disease with Oral Ulcers](#)
- Feb 15, 2018*
[OTEZLA[®] \(Apremilast\) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis](#)
- Feb 15, 2018*
[Celgene Corporation Elects John Weiland to Its Board of Directors](#)
- Feb 14, 2018*
[Celgene Announces Additional \\$5 Billion Share Repurchase Authorization](#)

Financials [\[View all \]](#)

- Feb 7, 2018*
[Annual Report \(10-K\)](#)
- Apr 27, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Oct 26, 2017*
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*
[Quarterly Report \(10-Q\)](#)